Organizational impact of systematic urine culture before Bacillus Calmette Guerin (BCG) induction instillations

World J Urol. 2025 May 19;43(1):316. doi: 10.1007/s00345-025-05671-9.

Abstract

Purpose: There are conflicting recommendations concerning the performance of a systematic urine culture (UC) prior to Bacillus Calmette Guerin (BCG) bladder instillations for non-muscle-invasive bladder tumor. The objective was to study the organizational impact of the UC performed before bladder instillations, defined as the number and proportion of BCG instillations postponed due to a positive urine culture result.

Methods: Induction BCG records in a single academic center between 2015 and 2020 were retrospectively reviewed. All patients had a UC prior to each instillation, treated if positive. Risk factors associated with the occurrence of a positive UC, an adverse event or postponement of instillation were studied.

Results: A total of 156 patients were included, among which 68.9% of patients had at least one risk factor of UTI and 33% of patients presented at least one positive UC at induction. During BCG induction, 76/909 (8.4%) urine cultures performed were positive and 33% of patients had at least one postponement of BCG instillation. There were 64 instillations postponed, caused by untreated positive urine culture for 40 (62.5%) and absence of urine culture performed for 6 (9.4%) In multivariate analysis, only the presence of lower urinary tract symptoms was significantly associated with a risk of positive UC.

Conclusion: Positive UC during BCG instillations is a frequent event and a source of disorganization in BCG induction, with possible oncological consequences. A strategy of performing UC only in selected patients, could facilitate proper BCG administration and avoid unreasonable use of antibiotics.

Keywords: Antibioprophylaxy; BCG; Non-invasive bladder tumor; Urinary tract infection; Urine culture.

MeSH terms

  • Adjuvants, Immunologic* / administration & dosage
  • Adjuvants, Immunologic* / therapeutic use
  • Administration, Intravesical
  • Aged
  • BCG Vaccine* / administration & dosage
  • BCG Vaccine* / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Urinalysis*
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / urine
  • Urinary Tract Infections* / microbiology
  • Urinary Tract Infections* / prevention & control
  • Urine* / microbiology

Substances

  • BCG Vaccine
  • Adjuvants, Immunologic